OMass Therapeutics
South East
British Patient Capital’s Future Fund: Breakthrough
OMass Therapeutics is an Oxford-based biotechnology company that discovers and develops novel small molecule medicines in areas of immunology and rare diseases where there are high, unmet clinical need.
Originally spun out of Oxford University, OMass has commercialised Professor Dame Carol Robinson’s breakthrough research in native mass spectrometry and developed to develop its proprietary drug discovery platform, OdyssION™.
British Patient Capital has invested £10m in the business as part of OMass’ Series B extension.
This financing will support OMass’ advance towards clinical development while also enabling the expansion of its pipeline.
Download The Power of 10:10 Year Impact Report
The Power of 10:10 Year Impact Report sets out how the British Business Bank has supported more than 200,000 businesses to prosper and grow over the last decade.
26,000
businesses supported
316,000
jobs supported
£13bn
additional turnover expected to be created
£6bn
additional GVA expected to be created
30,000
new jobs expected to be created